Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the association of bevacizumab and PDT is safety and effective in the treatment of exudative AMD

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Federal University of São Paulo
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• more or iqual 50 years old

• male or female

• Choroidal neovascularization sub or just foveal the fovea secondary to AMD (Predominantly Classic, Minimally Classic, and Occult lesions acceptable)

• Greatest linear dimension (GLD) of entire lesion < 5400 µm (no reading center confirmation required)

• ETDRS best corrected visual acuity of 20/40 - 20/320 (73 - 24 letter score)

• Total area of lesion must < 9 MPS DA

Exclusion Criteria:

• pre-treatment

• ETDRS best corrected visual acuity better than 34 letters

• macular surgery history

• laser photocoagulation in the study eye within 30 dais

• eye surgery within 30 days

• history of no-treat glaucoma

• acuite uveits

• history of endophthalmites

• vitreous hemorrhage

• geographic atrophy or fibrosis corresponding > 50% of the lesion